HC Wainwright Analysts Decrease Earnings Estimates for ABEO

Abeona Therapeutics Inc. (NASDAQ:ABEO) – Analysts at HC Wainwright reduced their Q1 2026 EPS estimates for shares of Abeona Therapeutics in a research note issued to investors on Monday, August 18th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will earn $0.04 per share for the quarter, down from their previous forecast of $0.05. HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported $1.71 EPS for the quarter, beating the consensus estimate of ($0.39) by $2.10. The company had revenue of $0.40 million during the quarter, compared to the consensus estimate of $21.71 million.

Several other equities analysts also recently commented on the stock. Wall Street Zen downgraded shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 15th. Oppenheimer increased their price objective on shares of Abeona Therapeutics from $19.00 to $20.00 and gave the company an “outperform” rating in a research note on Friday, August 15th. Alliance Global Partners reaffirmed a “buy” rating on shares of Abeona Therapeutics in a research note on Thursday, May 15th. Finally, Stifel Nicolaus cut their price target on shares of Abeona Therapeutics from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, May 16th. Five research analysts have rated the stock with a Buy rating, According to MarketBeat, Abeona Therapeutics currently has an average rating of “Buy” and a consensus target price of $19.50.

Abeona Therapeutics Price Performance

Shares of NASDAQ:ABEO opened at $6.84 on Tuesday. The company has a market cap of $350.76 million, a price-to-earnings ratio of 9.77 and a beta of 1.55. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.73 and a quick ratio of 4.90. The firm has a 50 day simple moving average of $6.25 and a 200 day simple moving average of $5.76. Abeona Therapeutics has a one year low of $3.93 and a one year high of $7.54.

Insider Activity at Abeona Therapeutics

In related news, SVP Brendan M. O’malley sold 17,428 shares of Abeona Therapeutics stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $5.86, for a total transaction of $102,128.08. Following the completion of the transaction, the senior vice president owned 360,817 shares of the company’s stock, valued at $2,114,387.62. This trade represents a 4.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mark Alvino sold 13,093 shares of Abeona Therapeutics stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $5.86, for a total transaction of $76,724.98. Following the transaction, the director directly owned 77,252 shares of the company’s stock, valued at $452,696.72. This represents a 14.49% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 231,626 shares of company stock valued at $1,430,587 in the last quarter. Insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Abeona Therapeutics

Hedge funds have recently bought and sold shares of the company. Ameritas Investment Partners Inc. bought a new position in Abeona Therapeutics during the second quarter worth $25,000. Legal & General Group Plc bought a new position in Abeona Therapeutics during the second quarter worth $27,000. Twinbeech Capital LP bought a new position in Abeona Therapeutics during the fourth quarter worth $58,000. Riverwater Partners LLC bought a new position in Abeona Therapeutics during the second quarter worth $62,000. Finally, Police & Firemen s Retirement System of New Jersey bought a new position in Abeona Therapeutics during the second quarter worth $63,000. Institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.